FRACTYL HEALTH INC
GUTSNASDAQTrading Snapshot
- Day Range
- $0.69 – $0.70
- 52-Week Range
- $0.38 – $2.45
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 158.7M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $93,000
- Last Q Revenue
- $25,867
- P/E Ratio
- —
- P/S Ratio
- 1151.5x
- EPS (TTM)
- $-2.07
- Dividend Yield
- —
Why Investors Own GUTS
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About FRACTYL HEALTH INC
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsBrian Luque - Head of Investor Relations & Corporate...
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of $(0.57) per share from
Fractyl Health to Participate in Upcoming Investor Events
BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: BTIG Virtual Biotechnology ConferenceFormat: One-on-one meetingsDates: July
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation July 15, 2026 8:00 AM...
These stocks are moving in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.